Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TxCell and Ferring International Center Sign Agreement

Published: Saturday, March 15, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
Collaboration, option, development and license agreement for TxCell’s lead product Ovasave® for the treatment of IBD.

TxCell SA and Ferring International Center SA have announced the signing of a collaboration, option, development and license agreement potentially worth up to EUR 76 million plus royalties subject to the achievement of milestones.

In the agreement, TxCell has granted Ferring an option to acquire an exclusive worldwide license for the development, manufacture and marketing of TxCell’s lead candidate Ovasave for the treatment of IBD, including Crohn's disease and ulcerative colitis.

TxCell will undertake a forthcoming phase IIb study with Ovasave in refractory Crohn’s disease. Ferring will then be responsible for the conduct and funding of further development and commercialization after the exercise of the option. There are currently around 100,000 refractory Crohn’s patients per year in Europe and in the US alone for whom there is no therapeutic treatment.

Initially, TxCell will receive EUR 3 million for the acquisition of the option by Ferring, of which EUR 1 million was paid upon signature of the agreement and the remainder will be paid depending on the progress of the Ovasave phase IIb trial planned to start in the second half of 2014.

TxCell will also be eligible in the future in the event of the exercise of the option to development, commercial and manufacturing milestones and payments up to a total of EUR 73 million. TxCell will also receive tiered royalties up to double digits on future sales of Ovasave.

“This agreement between TxCell and Ferring is a key milestone for TxCell,” said Damian Marron, CEO, TxCell. “The alliance of TxCell’s unique personalized cellular immunotherapy technology with Ferring’s renowned expertise in IBD will ensure that TxCell’s lead product, Ovasave, can be developed effectively and marketed globally to the sufferers of refractory Crohn’s disease. The agreement underlines the value of TxCell’s ASTrIA platform and the quality of the work of TxCell’s research, development and manufacturing teams”.

“This agreement reinforces Ferring’s continued commitment to bringing innovative therapies to patients suffering from gastrointestinal diseases. Ovasave represents an exciting potential addition to our current gastroenterology product portfolio,” said Pascal Danglas, Executive Vice President, Clinical and Product Development and member of the Executive Board of Ferring International Center SA.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Strengthening of Cash Position and Development of ASTrIA Product Platform
Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.
Tuesday, April 07, 2015
TxCell to Present at Upcoming US and French Investment Conferences
Conferences include Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25 and the Portzamparc PEA-PME Forum, Paris, April 1.
Saturday, March 28, 2015
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
Patent ensures protection for Ovasave® in the US until 2030 minimum.
Thursday, March 19, 2015
TxCell to Present at ROTH Capital Partners Investor Conference in US
TxCell invited to speak at largest US meeting for investors in emerging growth companies.
Friday, February 27, 2015
TxCell Reports Revenues for 2014 and Updates on Upcoming Milestones
Ovasave and Col-Treg regulatory status update in the United States, expected mid-2015.
Thursday, February 05, 2015
TxCell Receives EUR 1 Million Milestone Payment
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease.
Thursday, January 29, 2015
TxCell to Present at the Cell & Gene Therapy Forum 2015
Company to present its experience with Cell Therapy at the Cell & Gene Therapy Forum 2015, Washington.
Saturday, January 24, 2015
TxCell Receives EU Orphan Drug Designation for Col-Treg
A proof of principle clinical study is planned to start in the first half of 2015, with top line results of this study expected mid-2016.
Friday, December 19, 2014
TxCell Announces Start of Phase IIb Clinical Trial with Ovasave®
Top line results of this study are expected end 2016/early 2017.
Tuesday, December 09, 2014
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
Wednesday, October 29, 2014
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!